
5 Ways To Align With Your Best Self And Perform At Your Highest Level
We all have two competing versions inside us. Your higher self walks with confidence, stays present, and never rushes through life. This is your best state. Powerful, calm, and in control. Your lower self is the opposite. Impatient, restless, antsy. Always chasing the next dopamine hit, never satisfied with now.
Most people just accept whichever version shows up that day. They don't realize they have a choice. But you do.
Top performers recognise when their different versions show up. They can shift their state quickly. The same person feeling frustrated and rushed in the kitchen can transform into focused intensity seconds later for a presentation. They get in the zone in seconds.
Higher self versus lower self: know the difference
Your higher self sees life with clarity. Problems shrink to their actual size. You are chill where others are stressed. Your breathing slows. Your shoulders drop. But your lower self magnifies every issue. That email becomes a crisis. That comment becomes an attack. That delay becomes a catastrophe. Your breathing gets shallow. Your muscles tighten. Your voice pitches higher.
Your higher self responds thoughtfully, taking time to consider options before acting, while your lower self reacts instantly, often saying things you later regret. In meetings, your higher self asks clarifying questions and builds on ideas; your lower self interrupts, defends, and needs to be right.
Your happiness, work and life quality comes down to which self you embody most often. Luckily, you can change states within seconds once you know how.
Five ways to shift to your higher self immediately
Your body sends signals when you've dropped into your lower state. Maybe it's tightness in your chest. Or a buzzing in your head. Or tension between your shoulders. These physical symptoms arrive before the mental spiral. Catch them early.
Create a checklist of your personal triggers. When they show up, name them: "This is my lower self taking control." It takes practice, but you'll begin noticing their presence more often. Next time, you catch them quicker. Awareness itself begins the shift.
Have specific actions ready for when you notice yourself slipping. Make them simple and accessible anywhere. It might be eating a healthy meal. Taking a five-minute walk. Listening to a specific song. Reciting a mantra. Drinking water. Breathing deeply ten times.
Keep this list on your phone or a post-it note by your laptop. Reference it when those physical triggers appear. These small pattern interrupts work better than you'd think.
You can't jump straight from frustration to joy. The gap is too wide. But you can move from frustration to annoyance. From annoyance to acceptance. From acceptance to contentment. From contentment to optimism.
Know which emotions sit just above your current state. Aim for those first, not the top of the emotional guidance scale. Telling someone to "cheer up" never works. You need to meet them where they are, then guide them one step higher. Apply the same approach to your own disposition and watch it change with ease.
Ask yourself: "Am I actually upset, or do I just think I'm upset because I'm in a pattern from something that once upset me?" We develop emotional default settings through repetition. Your brain creates shortcuts. The meeting is delayed, so you get frustrated, because meetings that get delayed have frustrated you before.
First step, notice when you're in your lower self purely out of habit. Awareness enables the switch. Then, to get out of the habit, challenge the behaviours you have been defaulting to. Recognise that the situation itself holds no inherent emotion. Your interpretation creates your experience. Change that perspective and you change everything.
At any moment, you can decide who you want to be. Your higher or lower self. Nothing is fixed. Make it a game. When you feel yourself in that lower state, say: "Not today." Then consciously select your higher self. Smile, even when you don't feel like it. The act of smiling releases endorphins until you feel happy for real.
Naming your higher and lower self versions might help take this further. The more you practice returning to your optimal state, the more it becomes your default. Recognize challenges and rise above.
Choose your higher self now
Your higher self is already within you, waiting for you to claim it. Recognise your physical triggers. Create your intervention list. Understand the emotional guidance scale. Question your patterns. Exercise your power to choose. These five practices don't require years of meditation or therapy. They require awareness and decision, moment by moment. Step into your power.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador
Henry to utilize Amazfit products to optimize health, recovery and performance as he enters his 10th NFL season MILPITAS, Calif., July 18, 2025--(BUSINESS WIRE)--Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambassadors. Known for his rare combination of speed and strength, Henry will utilize Amazfit wearables to power every phase of his training, recovery and sleep as he prepares for his 10th NFL season. As one of the most prolific running backs of his generation, Henry has amassed an impressive array of accolades during his career, including NFL Offensive Player of the Year, two rushing titles, and five Pro Bowl selections. With Amazfit as his official smart wearable partner, the former Heisman winner will integrate advanced health and fitness tracking into his training regimen and recovery routine using Amazfit's performance-focused smartwatches, fitness wearables and the Zepp App. "As I progress in my career it's important to properly track my training and recovery so my body is ready for the on-field challenge every Sunday," said Henry. "Amazfit and the T-Rex 3 give me the tools to do this. From tracking my heart rate and training load to making sure I recover properly with sleep and stress monitoring, this partnership will help me take maintain peak performance week in and week out." As he enters his 10th NFL season, Henry is doubling down on optimizing his health and recovery to extend his dominance on the field. Following one of the most productive seasons of his career, Henry has been training this offseason with the Amazfit T-Rex 3, using it to monitor key health metrics, recovery indicators, and sleep quality. Paired with the Zepp App, he can tap into AI-powered insights, track nutrition with the Food Log and use the all new BioCharge feature that measures changes in body energy throughout the day, all designed to help him perform at the highest level throughout the season. "Derrick is one of the most respected and hardworking athletes in sports today, and his relentless drive to be the best mirrors our mission at Amazfit to help people unlock their full potential. We're excited to support his training journey as he prepares for the upcoming season and provide valuable insights to ensure he's performing at his best," said Wayne Huang, Founder & CEO of Zepp Health. Henry joins a growing lineup of Amazfit athlete ambassadors, including Olympic gold medalist Gabby Thomas, HYROX world champions Meg Jacoby and Hunter McIntyre, Padel star Bea González, triathlete Morgan Pearson, distance runner Yemaneberhan "Yeman" Crippa, and WTA top-10 tennis player Jasmine Paolini. Amazfit remains committed to empowering holistic health by supporting the four pillars of wellness: fitness, sleep, mindfulness, and nutrition. Whether tracking progress during high-impact workouts, optimizing recovery through sleep and readiness insights, or staying mindful with stress monitoring, Amazfit delivers a comprehensive approach to health that matches the intensity of world-class athletes like Henry. Explore the full range of Amazfit smart wearables and experience innovation that elevates performance, recovery, and precision at For more information, please visit and follow us on Facebook, Instagram, Twitter and YouTube. About Amazfit Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets. Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, "Discover Amazing," encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health's proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals. Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit View source version on Contacts Media Contact Mary Thompson WoodburyHead of PR, North


Forbes
4 days ago
- Forbes
Cigna Profits Hit $1.5 Billion Despite Higher Costs
The Cigna Group reported a second quarter profit of $1.5 billion as its Evernorth health service business performs well and despite rising costs in its employer health benefits business. Cigna, which includes Evernorth and one of the nation's largest pharmacy benefit management companies, said net income was $1.5 billion, or $5.71 per share in the second quarter of this year. That compares with $1.5 billion, or $5.45 per share, in the second quarter 2024. Meanwhile, total revenues for the second quarter 2025 rose 11% to $67.2 billion. 'Adjusted income from operations for second quarter 2025 increased 1% relative to second quarter 2024, reflecting strong growth in Evernorth Health Services and improvement in Corporate, partially offset by expected higher stop loss medical costs in Cigna Healthcare,' the company said. Cigna's medical cost issues are different than those of health insurance industry rivals that have struggled largely in their businesses providing government-subsidized health insurance coverage such as Medicaid benefits for the poor and Medicare Advantage for the elderly. Cigna earlier this year completed the sale of its Medicare businesses to Health Care Service Corp., an operator of Blue Cross and Blue Shield plans in five states. In Cigna's case, the company Thursday said its results were impacted by higher 'stop loss medical costs.' Under such policies, Cigna becomes liable for losses that exceed certain limits set up between the insurer and an employer's self-funded policy. Cigna didn't disclose the specific reason for the higher cost in its stop loss offering. But the stop loss offering impacted Cigna's medical cost ratio, which is the percentage of premium revenue that goes toward medical costs. Cigna's medical cost ratio increased in the second quarter to 83.2% compared to 82.3% in the year-ago period. Despite the stop loss issue, Cigna reaffirmed its 2025 outlook for adjusted income from operations of "at least $29.60 per share.' 'Listening, adapting, and innovating to meet the evolving needs of our patients, customers, and clients enables us to deliver meaningful value,' David M. Cordani, chairman and CEO of The Cigna Group said in a statement accompanying the company's second quarter earnings report. 'Our performance in the second quarter reflects our disciplined execution and the strength of our business mix.' Cigna's Evernorth health services business, which includes one of the nation's largest pharmacy benefit management companies in Express Scripts, grew 'existing client relationships' and experienced 'strong specialty pharmacy growth,' the company said. 'Total pharmacy customers at June 30, 2025 increased 3% from December 31, 2024 to 121.9 million due to new sales and the continued expansion of relationships,' Cigna said.


Medscape
5 days ago
- Medscape
Novel Combo Boosts Survival in IDH1-Mutated AML
TOPLINE: Ivosidenib combined with azacitidine extended median overall survival to 29.3 months compared with 7.9 months for placebo plus azacitidine in newly diagnosed isocitrate dehydrogenase 1 (IDH1)-mutated acute myeloid leukemia (AML). The combination therapy also improved hematologic recovery and increased transfusion independence rate to 53.8% vs 17.1% with placebo. METHODOLOGY: A total of 148 patients with newly diagnosed IDH1-mutated AML who were unfit for intensive chemotherapy were randomized to receive either ivosidenib-azacitidine (n = 73) or placebo-azacitidine (n = 75). Treatment consisted of 500 mg ivosidenib or placebo administered orally once daily, combined with subcutaneous or intravenous 75 mg/m² azacitidine for 7 days in 28-day cycles, with randomization stratified by geographic region and disease status. Analysis included a median follow-up period of 28.6 months, with overall survival as the key outcome measure, along with hematologic recovery, transfusion independence, and molecular measurable residual disease response. TAKEAWAY: Median overall survival was significantly longer with ivosidenib-azacitidine at 29.3 months (95% CI, 13.2-not reached) compared to 7.9 months (95% CI, 4.1-11.3) with placebo-azacitidine (hazard ratio [HR], 0.42; 95% CI, 0.27-0.65; P < .0001). Among patients who were transfusion dependent at baseline, conversion to transfusion independence was achieved in 53.8% (21/39) of ivosidenib-azacitidine patients vs 17.1% (7/41) of placebo-azacitidine patients (P = .0004). Of 33 ivosidenib-treated patients evaluable for molecular measurable residual disease, 10 (30.3%) achieved MRD negativity by day 1 of cycle 14, all of whom had complete remission. The safety profile remained consistent with previous reports, with lower rates of febrile neutropenia and infections in the ivosidenib-azacitidine arm, though neutropenia and bleeding events were more common than with placebo. IN PRACTICE: 'These long-term efficacy and safety results confirm the benefit of ivosidenib-azacitidine in this challenging-to-treat population and support its use as a standard of care with the longest reported survival benefit for intensive chemotherapy-ineligible patients with IDH1-mutated AML,' the authors of the study wrote. SOURCE: The study was led by Pau Montesinos, Hospital Universitari i Politécnic La Fe in Valencia, Spain, and Hartmut Döhner, Ulm University Hospital in Ulm, Germany. It was published online in Blood Advances. LIMITATIONS: According to the authors, molecular response analysis was limited by the small number of measurable residual disease-evaluable patients and samples, as well as the discontinuation of sample collection after study unblinding in March 2021. The limited number of variants that could be tracked with sufficient sensitivity in panel-based next-generation sequencing measurable residual disease assessment also constrained the molecular analyses. DISCLOSURES: Montesinos disclosed having relationships with AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, Servier, and Teva Pharmaceuticals. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.